FDA 483 - Mission Pharmacal Company - February 07, 2014

An FDA inspection of Mission Pharmacal Co, a drug manufacturer, identified a repeat observation concerning the lack of written procedures for in-process controls and testing. The firm failed to conduct in-process blend sample testing for prenatal products, exemplified by CitraNatal Assure tablets. This indicates a significant and recurring issue with quality control processes.